115 related articles for article (PubMed ID: 32590338)
1. Tyrosine kinase inhibitor therapy and metabolic remodelling in papillary thyroid cancer.
Wagner M; Wuest M; Lopez-Campistrous A; Glubrecht D; Dufour J; Jans HS; Wuest F; McMullen TPW
Endocr Relat Cancer; 2020 Sep; 27(9):495-507. PubMed ID: 32590338
[TBL] [Abstract][Full Text] [Related]
2. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Zhang XY; Sun ZK; Luo QY
J Mol Endocrinol; 2017 Jan; 58(1):15-23. PubMed ID: 27920093
[TBL] [Abstract][Full Text] [Related]
3. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
4. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
Nagarajah J; Ho AL; Tuttle RM; Weber WA; Grewal RK
J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
[TBL] [Abstract][Full Text] [Related]
5. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
6.
Eschbach RS; Kazmierczak PM; Heimer MM; Todica A; Hirner-Eppeneder H; Schneider MJ; Keinrath G; Solyanik O; Olivier J; Kunz WG; Reiser MF; Bartenstein P; Ricke J; Cyran CC
Cancer Imaging; 2018 Jan; 18(1):2. PubMed ID: 29347968
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
8. THE RELATIONSHIP OF BRAF
Santhanam P; Khthir R; Solnes LB; Ladenson PW
Endocr Pract; 2018 Jan; 24(1):21-26. PubMed ID: 29144823
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL
J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977
[TBL] [Abstract][Full Text] [Related]
10. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Kelly CJ; Hussien K; Muschel RJ
Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
[TBL] [Abstract][Full Text] [Related]
11. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases.
Sikorska J; Gaweł D; Domek H; Rudzińska M; Czarnocka B
BMC Cancer; 2019 Jan; 19(1):85. PubMed ID: 30654768
[TBL] [Abstract][Full Text] [Related]
12.
Jiang Y; Zeng Q; Jiang Q; Peng X; Gao J; Wan H; Wang L; Gao Y; Zhou X; Lin D; Feng H; Liang S; Zhou H; Ding J; Ai J; Huang R
Theranostics; 2022; 12(14):6395-6408. PubMed ID: 36168616
[No Abstract] [Full Text] [Related]
13. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973.
Baudy AR; Dogan T; Flores-Mercado JE; Hoeflich KP; Su F; van Bruggen N; Williams SP
EJNMMI Res; 2012 May; 2(1):22. PubMed ID: 22651703
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+/I- symporter in patients with untreated papillary thyroid carcinoma.
Moon SH; Oh YL; Choi JY; Baek CH; Son YI; Jeong HS; Choe YS; Lee KH; Kim BT
Endocr Res; 2013; 38(2):77-84. PubMed ID: 22888973
[TBL] [Abstract][Full Text] [Related]
16. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
[TBL] [Abstract][Full Text] [Related]
17. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
18. Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells.
Ghezzi C; Perez S; Ryan K; Wong A; Chen BY; Damoiseaux R; Clark PM
Mol Imaging Biol; 2023 Jun; 25(3):541-553. PubMed ID: 36284040
[TBL] [Abstract][Full Text] [Related]
19. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
20. CD147-mediated glucose metabolic regulation contributes to the predictive role of
Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
